@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_head { this: np:hasAssertion dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_assertion; np:hasProvenance dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_provenance; np:hasPublicationInfo dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_publicationInfo; a np:Nanopublication . dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_assertion a np:Assertion . dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_provenance a np:Provenance . dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_publicationInfo a np:PublicationInfo . } dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_assertion { miriam-gene:6347 a ncit:C16612 . lld:C0006118 a ncit:C7057 . dgn-gda:DGN07966cce2a549c49e2f4bce8ce55c822 sio:SIO_000628 miriam-gene:6347, lld:C0006118; a sio:SIO_001121 . } dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_provenance { dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_assertion dcterms:description "[Specifically, we aimed to optimize the therapeutic efficacy of Flt3L/TK treatment in the RG2 model by overexpressing the following genes within the brain tumor microenvironment: 1) a TK mutant with enhanced cytotoxicity (SR39 mutant TK), 2) Flt3L-IgG fusion protein that has a longer half-life, 3) CD40L to stimulate DC maturation, 4) T helper cell type 1 polarizing dendritic cell cytokines interleukin-12 or C-X-C motif ligand 10 chemokine (CXCL)-10, 5) C-C motif ligand 2 chemokine (CCL2) or C-C motif ligand 3 chemokine (CCL3) to enhance dendritic cell recruitment into the tumor microenvironment, 6) T helper cell type 1 cytokines interferon-γ or interleukin-2 to enhance effector T-cell functions, and 7) IκBα or p65RHD (nuclear factor kappa-B [NF-κB] inhibitors) to suppress the function of Foxp3+ Tregs and enhanced effector T-cell functions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:22996231; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP408274.RASOY9FuRN7DRAu0258JtQgP_YFKo8mfNq6j_T7jII8sE130_publicationInfo { this: dcterms:created "2014-10-02T12:36:02+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }